JP6482533B2 - クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 - Google Patents

クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 Download PDF

Info

Publication number
JP6482533B2
JP6482533B2 JP2016514143A JP2016514143A JP6482533B2 JP 6482533 B2 JP6482533 B2 JP 6482533B2 JP 2016514143 A JP2016514143 A JP 2016514143A JP 2016514143 A JP2016514143 A JP 2016514143A JP 6482533 B2 JP6482533 B2 JP 6482533B2
Authority
JP
Japan
Prior art keywords
seq
subject
variants
tnfsf15
locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016514143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526875A (ja
JP2016526875A5 (enExample
Inventor
ダーモット ピー． マクガバーン，
ダーモット ピー． マクガバーン，
Original Assignee
セダーズ−シナイ メディカル センター
セダーズ−シナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セダーズ−シナイ メディカル センター, セダーズ−シナイ メディカル センター filed Critical セダーズ−シナイ メディカル センター
Publication of JP2016526875A publication Critical patent/JP2016526875A/ja
Publication of JP2016526875A5 publication Critical patent/JP2016526875A5/ja
Application granted granted Critical
Publication of JP6482533B2 publication Critical patent/JP6482533B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016514143A 2013-05-17 2014-05-16 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 Active JP6482533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17
US61/824,932 2013-05-17
PCT/US2014/038468 WO2014186750A2 (en) 2013-05-17 2014-05-16 Variants of tnfsf15 and dcr3 associated with crohn's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018124311A Division JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Publications (3)

Publication Number Publication Date
JP2016526875A JP2016526875A (ja) 2016-09-08
JP2016526875A5 JP2016526875A5 (enExample) 2017-06-15
JP6482533B2 true JP6482533B2 (ja) 2019-03-13

Family

ID=51899024

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016514143A Active JP6482533B2 (ja) 2013-05-17 2014-05-16 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Country Status (7)

Country Link
US (4) US20160090629A1 (enExample)
EP (3) EP2997165A4 (enExample)
JP (5) JP6482533B2 (enExample)
KR (4) KR102295125B1 (enExample)
CN (1) CN105358713B (enExample)
ES (1) ES2894963T3 (enExample)
WO (1) WO2014186750A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
CN105358713B (zh) 2013-05-17 2020-02-28 雪松-西奈医学中心 与克罗恩病相关的tnfsf15和dcr3的变体
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CA2994719A1 (en) 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CN109476698B (zh) * 2016-05-20 2023-10-17 西达-赛奈医疗中心 基于基因的炎性肠病诊断
CN121371183A (zh) 2018-09-07 2026-01-23 费城儿童医院 用于淋巴系统病症的诊断和治疗的组合物和方法
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
CN121949515A (zh) * 2019-09-13 2026-05-01 协和麒麟株式会社 DcR3变体
JP2023551602A (ja) * 2020-11-13 2023-12-08 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
HRP20150684T1 (hr) 2008-02-19 2015-09-11 The Children's Hospital Of Philadelphia, Abramson Pediatric Research Center, Office of Technology Transfer Identifikacija specifiäśnih mjesta nastanka - genetski loci - upalne bolesti crijeva kod djece i postupci njihove uporabe u takvoj dijagnozi te njihovo lijeäśenje
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
NZ595471A (en) * 2009-04-14 2014-01-31 Nestec Sa Inflammatory bowel disease prognostics
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
ES2530175T3 (es) 2011-02-17 2015-02-26 Nestec S.A. Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2012174338A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
EP2769321B1 (en) 2011-10-21 2016-06-01 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
CN105358713B (zh) 2013-05-17 2020-02-28 雪松-西奈医学中心 与克罗恩病相关的tnfsf15和dcr3的变体
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법

Also Published As

Publication number Publication date
US20250243548A1 (en) 2025-07-31
JP2018148931A (ja) 2018-09-27
JP2022111329A (ja) 2022-07-29
JP2025023316A (ja) 2025-02-14
KR20210107176A (ko) 2021-08-31
US20180230543A1 (en) 2018-08-16
JP2020127437A (ja) 2020-08-27
JP2016526875A (ja) 2016-09-08
WO2014186750A3 (en) 2015-01-08
KR20160009582A (ko) 2016-01-26
KR102295125B1 (ko) 2021-08-31
US20160090629A1 (en) 2016-03-31
CN105358713A (zh) 2016-02-24
US12281359B2 (en) 2025-04-22
EP3498867A1 (en) 2019-06-19
ES2894963T3 (es) 2022-02-16
EP3988673A2 (en) 2022-04-27
EP2997165A2 (en) 2016-03-23
US20210371931A1 (en) 2021-12-02
EP3498867B1 (en) 2021-09-29
EP2997165A4 (en) 2017-03-08
KR20230093538A (ko) 2023-06-27
WO2014186750A2 (en) 2014-11-20
ES2894963T8 (es) 2022-02-24
EP3988673A3 (en) 2022-08-03
KR20250130857A (ko) 2025-09-02
CN105358713B (zh) 2020-02-28

Similar Documents

Publication Publication Date Title
JP2018148931A (ja) クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
Maltby et al. Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients
Vanita et al. A novel mutation in the DNA‐binding domain of MAF at 16q23. 1 associated with autosomal dominant “cerulean cataract” in an Indian family
KR20130130732A (ko) 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측
EP2158330A2 (en) Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
US20160096885A1 (en) Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
Schapiro et al. Panel sequencing distinguishes monogenic forms of nephritis from nephrosis in children
JP6689743B2 (ja) 抑うつ症状及び不安症状の少なくとも一方を有する患者におけるバソプレッシン受容体１ｂアンタゴニストに対する治療応答を予測する方法
AU2006220604A1 (en) Diagnostic and therapeutic target for macular degeneration
CN1681941A (zh) 基于ApoE基因型治疗痴呆的方法
Evans et al. Novel 25 kb deletion of MERTK causes retinitis pigmentosa with severe progression
Nasri et al. A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population
HK40072596A (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
JP7090604B2 (ja) びまん性大細胞型ｂ細胞リンパ腫の予後予測因子、及び予後予測方法
Davoudi et al. Molecular analysis of ABCA4 gene in an Iranian cohort with Stargardt disease
Davatchi et al. HLA-B51 in Behçet’s disease
Khan et al. GENETIC RISK VARIANTS ARE COMMON IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS FROM MINORITIZED BACKGROUNDS
JP2008534019A (ja) ヒトニーマンピックｃ１様１遺伝子（ｎｐｃ１ｌ１）多型及びその使用方法
EP3174999A1 (en) Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
Hoffman Modeling Macular Degeneration Using Quantitative Phenotypes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190212

R150 Certificate of patent or registration of utility model

Ref document number: 6482533

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250